The Brighterside of News on MSN14h
New nighttime nasal spray significantly alleviates sleep apneaA nighttime nasal spray may offer a new way to ease sleep apnea and lower blood pressure, according to Australian researchers ...
Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...
Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...
Clinical Trials Arena on MSN2d
Beckley Psytech completes subjects’ enrolment for Phase IIb trial of TRD therapyBeckley Psytech has completed subject enrolment for the core stage of the global Phase IIb clinical trial of patent-protected ...
Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...
The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in ...
The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for severe allergic reactions and anaphylaxis.
Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...
The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and ...
Phenylephrine and pseudoephedrine are both active ingredients in nonprescription Sudafed products. However, phenylephrine has ...
Nasal Spray Innovation Offers Hope for Traumatic Brain Injury TreatmentA new study led by researchers at Mass General Brigham suggests a nasal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback